Redefining the standard of cardiac surgical care.
A medical technology company built around one critical moment in cardiac surgery.
Marizyme is a medical technology company dedicated to transforming cardiac surgical care. We bridge advanced biotechnology and clinical practice by developing first-in-class vascular conduit solutions for the most critical challenges in coronary artery bypass graft surgery.
Our mission is to safeguard patient outcomes through the maintenance of vascular integrity — using a proprietary platform designed to address oxidative damage during the intraoperative window.
FDA De Novo granted, Class II — the first device classification of its kind for intraoperative saphenous vein graft flushing and storage.
Clinical Innovation
The first and only FDA De Novo granted vascular conduit solution indicated to maintain cell viability and structural integrity of saphenous vein grafts during CABG surgery.
Partnership with Health Systems
We aim to give hospital systems a strategic tool that supports graft quality during CABG.
Strategic Scale
With a patent portfolio spanning more than 30 countries and national network agreements, Marizyme is built for long-term sustainability.
Talk to our team.
For clinical questions, evaluation requests, or Value Analysis Committee documentation.